Evidence map›Paper›PMID 35474996›Full record

ArticleClinical case reports2022

Irinotecan-induced severe hypotension in a patient with lung cancer.

Ryota Nakano, Kenji Momo, Airi Matsuzaki, Akiko Sakai, Takeshi Uchikura, Katsumi Tanaka, Satoshi Numazawa, Tadanori Sasaki

Open access · goldAbstract readCase Reports
In one paragraph

Article in Clinical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ryota NakanoDepartment of Pharmacy Izumi Memorial Hospital Adachi-ku Japan.
Kenji MomoDepartment of Hospital Pharmaceutics School of Pharmacy Showa University Shinagawa-ku Japan.ORCID https://orcid.org/0000-0001-9856-0097
Airi MatsuzakiDepartment of Pharmacy Izumi Memorial Hospital Adachi-ku Japan.
Akiko SakaiDepartment of Pharmacy Izumi Memorial Hospital Adachi-ku Japan.
Takeshi UchikuraDepartment of Hospital Pharmaceutics School of Pharmacy Showa University Shinagawa-ku Japan.
Katsumi TanakaDepartment of Hospital Pharmaceutics School of Pharmacy Showa University Shinagawa-ku Japan.
Satoshi NumazawaDivision of Toxicology Department of Pharmacology Toxicology and Therapeutics Showa University School of Pharmacy Shinagawa-ku Japan.
Tadanori SasakiDepartment of Pharmacy Showa University Hospital Shinagawa-ku Japan.
Showa University · JPShowa University Hospital · JPMitsui Memorial Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most hypotension during chemotherapy is caused by an allergic mechanism. Conversely, non-allergic hypotension due to chemotherapy is rare. In this case report, we present a patient who suffered severe hypotension followed by the administration of irinotecan-based chemotherapy and some supportive care such as steroids for preventing emesis. A 71-year-old man with hypertension was diagnosed with stage IV small cell lung cancer (sT1cN3M0). Severe hypotension occurred in the patient after every administration of chemotherapy. Finally, he was able to receive all four courses of chemotherapy as planned along with the medical staff's support care. This case provides that a regimen that contained irinotecan and steroid could cause hypotension and the mechanism is partially explained by inhibiting choline esterase and adrenal insufficiency. We should be careful about non-allergic hypotension when we administer irinotecan-based chemotherapy.

Indexed as

adverse effectschemotherapyirinotecannon‐allergic hypotension

Identifiers

PMID35474996
PMCPMC9021929
OpenAlexW4224228944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.